Positive FDA panel recommendation for Vanda’s tasimelteon

15 November 2013

The US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee has recommended approval (by a 10 to 0 vote, with one abstention) of Vanda Pharmaceutical's (Nasdaq: VNDA) New Drug Application for tasimelteon, proposed trade name Hetlioz, for the treatment of non-24-hour disorder (Non-24) in the totally blind.

Trading in Vanda stock was halted yesterday ahead of the advisory panel meeting, but the shares nearly doubled Tuesday after an FDA staff report said the drug is effective. However, in pre-market trading this morning, the shaes rose 22% to $15.91.

The advisory panel found that:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK